Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 4, 2004, Pages 1674-1683

  Pivonello, Rosario ^a   Matrone, Carmela ^a   Filippella, Mariagiovanna ^a   Cavallo, Luigi M ^a   Di Somma, Carolina ^a   Cappabianca, Paolo ^a   Colao, Annamaria ^a   Annunziato, Lucio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR;

ADULT; ALPHA CHAIN; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS TUMOR; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROSURGERY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROTEIN ISOFORMS; PROTEIN SUBUNITS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VISUAL FIELDS;

EID: 1942440916     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030859     Document Type: Article

References (50)

1. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG 1998 Dopamine receptors: from structure to function. Physiol Rev 78:189-225
2. De Camilli P, Macconi D, Spada A 1979 Dopamine inhibits adenylate cyclase in human prolactin secreting pituitary adenomas. Nature 278:252-254
3. Bression D, Brandi AM, Martres MP, Nousbaum A, Cesselin F, Racadot J, Peillon F 1980 Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. J Clin Endocrinol Metab 51:1037-1044
4. Molitch ME, Thorner MO, Wilson C 1997 Management of prolactinomas. J Clin Endocrinol Metab 82:996-1000
5. Colao A, Lombardi G 1998 Growth hormone and prolactin excess. Lancet 352:1455-1461
6. Colao A, Annunziato L, Lombardi G 1998 Treatment of prolactinomas. Ann Med 30:452-459
7. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904-909
8. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876-883
9. Bression D, Brandi AM, Martres MP, Nousbaum A, Le Dafniet M, Racadot J, Peillon F 1982 Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perfusion system. J Clin Endocrinol Metab 55:589-593
10. Pivonello R, Ferone D, de Herder WW, Kros JM, Del Basso De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SWJ, Dopamine receptor expession and function in corticotroph pituitary tumors. J Clin Endocrinol Metab, in press
11. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518-523
12. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
13. Lamberts SWJ, Klijn JGM, De Quijada M, Timmermans HAT, Ultterlinden P, De Jong FH, Birkenhager JC 1980 The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab 51:307-311
14. Invitti C, De Martin M, Danesi L, Cavagnini F 1995 Effect of injectable bromocriptine in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 103:266-271
15. Miller JW, Crapo L 1993 The medical treatment of Cushing's syndrome. Endocr Rev 14:443-458
16. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
17. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens J-L, Mahler C, Becker A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
18. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D 1998 Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516-521
19. Bevan JS, Burke CW 1986 Non functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf) 25:561-572
20. 2 receptor imaging in clinically non functioning pituitary macroadenomas and macroprolactinomas. Eur J Nucl Med 26:46-50
21. Wollesen F, Andersen T, Karle A 1982 Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 96:281-286
22. Grossman A, Ross R, Charlesworth M, Adams CBT, Wass JAH, Doniach I, Besser GM 1985 The effect of dopamine agonist therapy on large functionless pituitary tumors. Clin Endocrinol (Oxf) 22:679-686
23. Vance ML, Ridgeway EC, Thorner MO 1985 Follicle-stimulating hormone and α-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab 61:580-584
24. 2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 83:1368-1375
25. Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R, Paschke R 2001 Minor tumor shrinkage in non functioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4:173-178
26. Katnelson L, Alexander JM, Klibanski A 1993 Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 76:1089-1094
27. Grochowicki M, Vighetto A, Berquet S, Khalfallah Y, Sassolas G 1991 Pituitary adenomas: automatic static perimetry and Goldmann perimetry. A comparative study of 345 visual field charts. Br J Ophthalmol 75:219-221
28. Lundin P, Pedersen F 1992 Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16:519-528
29. Lamberts SWJ, MacLoad RM 1990 Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev 70:279-318
30. 2 receptor radioligand. Clin Endocrinol (Oxf) 45:755-767
31. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509
32. Colao A, Lombardi G, Annunziato L 2000 Cabergoline. Exp Opin Pharmacother 1:555-574
33. Petrossians P, Ronci N, Valdes-Socin H, Kalife A, Stevenaert A, Bloch B, Tabarin A, Beckers A 2001 ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144:51-57
34. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A 1999 Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22:860-865
35. Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, Kishimoto S, Mori S, Uozumi T 1987 Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol 114:595-602
36. Pirker W, Riedl M, Luger A, Czech T, Rossler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I., Brucke T Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med 37:1931-1937
37. Renner U, Mojto J, Lange M, Muller OA, von Werder K, Stalla GK 1994 Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 130:80-91
38. Kwekkeboom DJ, Lamberts SWJ 1992 Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma. Clin Endocrinol (Oxf) 36:171-176
39. Nobels FRE, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuijderwljk J, de Jong FH, Lamberts SWJ 2000 Long-term treatment with dopamine agonist quinagolide of patients with a clinically non-functioning pituitary adenoma. Eur J Endocrinol 143:615-621
40. Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G 1998 Correlation of scintigraphic results using 123I-metoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 83:248-252
41. Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G 2000 Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-metoxybenzamide. Clin Endocrinol (Oxf) 52:437-452
42. Harris PE, Afshar F, Coates P, Doniach I, Wass JA, Besser GM, Grossman A 1989 The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary tumours. Q J Med 71:417-427
43. Civelli O, Bunzow JR, Grandy DK 1993 Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 33:281-307
44. 2 dopamine receptor isoforms. Nature 342:923-926
45. Hayes G, Biden TJ, Selbie LA, Shine J 1992 Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol 6:920-926
46. Vallar L, Muca C, Magni M, Albert P, Bunzow J, Meldolesi J, Civelli O 1990 Differential coupling of dopaminergic D2 receptors expressed in different cell types. Stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis in LtK-fibroblasts, hyperpolarization, and cytosolic-free Ca2+ concentration decrease in GH4C1 cells. J Biol Chem 265:10320-10326
47. Montmayeur J-P, Guiramand J, Borrelli E 1993 Preferential coupling between dopamine D2 receptors and G-proteins. Mol Endocrinol 7:161-170
48. Lania A, Reza-Elahi F, Gil-del-Alamo P, Saccomanno K, Mantovani S, Spada A 1995 Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas. J Endocrinol Invest 18:265-270
49. Milligan G 2001 Oligomerisation of G-protein-coupled receptors. J Cell Sci 114:1265-1271
50. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:65-67